Similarly, ATTRACTION-3 is a phase 3 trial in advanced ESCC aimed at comparing nivolumab to chemotherapy and showed a significant OS benefit regardless of PD-L1 expression [79]. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.